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Abstract
Objective: Menopause is the consequence of exhaustion of the ovarian follicular pool. AMH, an indirect hormonal marker of
ovarian reserve, has been recently proposed as a predictor for age at menopause. Since BMI and smoking status are relevant
independent factors associated with age at menopause we evaluated whether a model including all three of these variables
could improve AMH-based prediction of age at menopause.
Methods: In the present cohort study, participants were 375 eumenorrheic women aged 19–44 years and a sample of 2,635
Italian menopausal women. AMH values were obtained from the eumenorrheic women.
Results: Regression analysis of the AMH data showed that a quadratic function of age provided a good description of these
data plotted on a logarithmic scale, with a distribution of residual deviates that was not normal but showed significant left-
skewness. Under the hypothesis that menopause can be predicted by AMH dropping below a critical threshold, a model
predicting menopausal age was constructed from the AMH regression model and applied to the data on menopause. With
the AMH threshold dependent on the covariates BMI and smoking status, the effects of these covariates were shown to be
highly significant.
Conclusions: In the present study we confirmed the good level of conformity between the distributions of observed and
AMH-predicted ages at menopause, and showed that using BMI and smoking status as additional variables improves AMH-
based prediction of age at menopause.
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Introduction
Age at menopause has relevant implications for female health
since late menopause is associated with increased risk of breast
cancer [1] and early menopause is associated with increased risk of
osteoporosis, cardiovascular disease, early cognitive decline,
ovarian cancer, colorectal cancer, respiratory and urogenital
disease [2,3,4,5,6].
More importantly, as women increasingly postpone childbirth,
prediction of an early menopause in young women could be of
increasing clinical value. The determinants of age at menopause
have been investigated in several studies [7,8] and the most
consistent finding is that early age at menopause is associated with
smoking and low BMI [8,9,10,11]. Less clear is the relationship
between the number of pregnancies and births and the use of
hormonal contraception [8].
Since menopause is the consequence of exhaustion of the
ovarian follicular pool, recent theories show convincingly that in
women of the same age, a larger pool of resting follicles may be
associated with a later age at menopause, whereas a smaller pool
may be a risk for early menopause [12,13,14].
Unfortunately to date there are no diagnostic methods to
measure directly the number of primordial follicles in the ovaries
of women, while several indirect ovarian reserve markers have
been developed and successfully tested [15,16,17]. Hormonal
(AMH, FSH, inhibin B) and ultrasound (antral follicle count –
AFC) markers are associated with antral follicles actually present
in the ovaries. However, since the population of antral follicles is
related to the number of primordial follicles [12] their determi-
nation permits assessment of the extent of the ‘‘true’’ ovarian
reserve (the number of non-growing follicles). AMH and AFC
have both been shown to have very good and highly significant
correlations (R.0.7; p-value,0.001) with the number of primor-
dial follicles as determined by modern stereology techniques from
histological analysis [18].
AMH has been recently proposed as a good predictor for age at
menopause [19,20,21], with all studies suggesting that in women of
similar age a lower serum AMH level may be indicative of an
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earlier age at menopause. Without data directly correlating AMH
with menopausal age, the methodology in ref.19 was based on
joint modelling of data on changing AMH with age and data on
menopausal ages, from two independent samples of women, using
a hypothesis that AMH falling below a critical threshold is
predictive of menopause. Predictions were based only on serum
AMH levels and age; however, since BMI and smoking status are
relevant independent factors associated with age at menopause, we
consider whether similar but more complex modelling including
these additional covariates (BMI and smoking) might improve
AMH-based predictions of age at menopause.
Materials and Methods
Study design and subjects
This cross-sectional study was based on methodology developed
in previous studies [19,22] and involved two independent samples
of women. One, a group of 375 healthy, regular cycling, caucasian
women aged 19–44 years, was recruited from women requiring
preconception counselling or undergoing cervical cancer and
breast cancer screening. Inclusion criteria for enrolment were:
normal menstrual cycles (length 25–35 days), not pregnant or
using hormones or drugs that interfere with the menstrual cycle,
no history of hysterectomy, miomectomy, oopherectomy, or any
other surgery on their ovaries. Patients included in the study had
no known chronic, systemic, metabolic or endocrine disease. All
women gave their written informed consent before blood sampling
for AMH determination. IRB approval was obtained.
A distribution of ages at menopause was obtained from another
sample of 2635 Italian women participating in the GOERM study
[23]. This GOERM study was a retrospective study focused on
clinical research on menopause for women living in the Italian
region of Emilia Romagna and involving four university hospitals
(Bologna, Ferrara, Parma and Modena). All women (age at the
time of inclusion ranged from 41 to 61 years of age) were
menopausal (physiological menopause defined as amenorrhea for
more than 12 months); the time since menopause was 2.360.02
years (mean 6 SEM), and for all women smoking habits and BMI
were known, with the latter categorised under-weight (BMI,18.5),
normal weight (18.5#BMI,25), over-weight (25#BMI,30) and
obese (BMI$30).
AMH assay
The blood sample for AMH determination was taken when the
patients were recruited, independently of the last menstrual cycle.
After 12-hour fasting, blood was taken from the cubital vein
between 8:00 a.m. and 12:00 noon The blood was centrifuged at
3500 cycles/minute for 10 minutes and the serum was stored in
polypropylene tubes at 280uC.
Serum AMH was measured by enzyme-linked immunosorbent
assay (ELISA) using the Beckman Coulter, Inc. (Chaska, MN,
USA) AMH ELISA kit (Immunotech version, Marseilles, France).
The detection limit of the assay was 0.14 ng/ml; imprecision of
the assay was 12.3% at 0.2 ng/ml and 5.1% at 15.8 ng/ml. The
immunoassay is specific for AMH. No cross-reaction was observed
with transforming growth factor-beta.
Statistical Analysis
Analyses were based on a methodology similar to that used in
previous work [19,22], and involved a two-stage modelling and
estimation process using the two data-sets (AMH measurements
and menopausal age). First, a robust regression analysis of the
logged AMH data as the response (or dependent variable) using
age, BMI and smoking status as covariates (or independent
variables) was carried out by maximum likelihood, using modelling
with a more general (longer-tailed than normal) skew-t residual
distribution as described in [24]. The estimated regression
equation and probability distribution of residual deviates estab-
lished a model for age-related change in AMH, from which age-
dependent AMH-percentiles (5%, 10%, 25%, 50%, 75%, 90%
and 95%) could be estimated.
The second stage uses the hypothesis [19] that occurrence of
menopause can be predicted by AMH falling below a critical
threshold level, which provides a link between the two data-sets
whereby menopause occurring before age y (say) corresponds to
AMH at age y being below this threshold. This enables a
probability distribution of menopausal ages to be determined from
the equation:
probability of age at menopausevy
~probability of log AMHð Þ at age yv log thresholdð Þ
using the previously estimated regression equation for the mean of
log(AMH) at age y. To allow for excess inter- and intra-cycle
variation in AMH from individual women [25] not contributing to
varying fertility between women, another skew-t probability
distribution [24] was used to describe the variation of log(AMH)
here. With log(threshold) a linear function of BMI and smoking
status (as in the usual regression context) probabilities on the right
hand side of the above equation can be determined. This
formulates a model for analysis of the GOERM data using
maximum likelihood estimation, where menopausal age is the
response and BMI and smoking status are covariates. Finally,
percentiles of menopausal age can be calculated from the
estimated BMI and smoking specific probability distributions of
menopausal age, similar to those for AMH.
Prediction of menopausal age for individual women follows a
similar two stage process. First, the woman’s AMH level and age is
located within age-dependent AMH percentiles (less than 5%,
between 5% and 10%, etc.), then her predicted age at menopause
can be inferred from similar percentiles of menopausal age.
Results
Characteristics of patients included in the study are reported in
Table 1. In the AMH cohort the percentage of smokers was
significantly higher than in the GOERM study. BMI was
significantly higher for women from GOERM than for those in
the AMH cohort, probably because women in the latter group
were younger than those in the former group, providing a prima
facie case for some allowance of these covariates (smoking and
BMI) in the analysis. In the GOERM data-set (n=2635), the mean
age at which women reported menopause was 49.460.8 years
(mean 6 SEM).
Table 1. Characteristics of patients in the AMH and GOERM
cohorts.
AMH GOERM
Significance of
difference
Age at inclusion
(mean 6 SEM)
35.360.2 52.560.1 p-value,0.05
Current or past smoker (%) 33.5 27.6 p-value,0.05
BMI (mean 6 SD) 23.264.2 2664.6 p-value,0.05
doi:10.1371/journal.pone.0057005.t001
Ovarian Reserve and Age at Menopause
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The regression analysis of the AMH data showed that age
(p-value,0.001) and age2 (p-value<0.03) were significant
predictors while BMI and smoking status were not
(p-values.0.20), giving (cf. the preferred model in [26]):
meanLog(AMH)={1:11+0:2|age{0:0400|age2
This quadratic function of age was very close to an estimate of
the mean obtained by smoothing the raw observations as in [19]
shown in Figure 1, with AMH declining from a peak at around
age 25 years. Additional terms involving age3 and age4 were not at
all significant (p-values.0.50), and BMI and smoking status also
had no significant effects on the rates of change with age (p-
values.0.17).
The distribution of the residual deviates (differences between
data values and estimated mean) was significantly (p-value,0.01)
non-normal showing left-skewness (relatively more subjects had
AMH levels above the estimated mean than below it) and was
adequately described by a skew-t distribution (goodness of fit
statistic 373.8 on 369 degrees of freedom). Estimated AMH-
percentiles from the resulting model are shown in Figure 2, with
the age range restricted to 25–45 years where the mean is
relatively well estimated (Figure 1). Notice that the estimated
median (50-percentile) is slightly larger than the estimated mean
(Figure 1), reflecting the left-skewness of the residual distribution.
Figure 2 indicates that an AMH level of 2.5 ng/mL from a 30-
year old woman, for example, would be between the 25- and 50-
percentiles.
The subsequent analysis of the GOERM data using the model
for menopausal ages derived from AMH falling below a critical
threshold dependent on BMI and smoking status (combined
additively in the log-threshold) showed significant effects of these
covariates (p-values,0.001). Some comparisons of the observed
and modelled cumulative frequency distributions of menopausal
age for different BMI categories and smoking status are displayed
in Figure 3, showing quite good concordance between these –
particularly for the normal and over-weight BMI categories which
covered most (80%) of the data. (No meaningful comparisons
could be made for the under-weight BMI category as only 15
observations were in this category.) The residual variance of
log(AMH) from this analysis was, significantly (p-value,0.001)
lower than that from the earlier regression analysis of log(AMH)
on age, by an estimated factor of 0.72 (95% confidence interval
0.62–0.85) consistent with some excess inter- and intra-cycle
variation in the AMH data. The estimated thresholds below which
AMH predicts menopause are shown in Table 2, for non-smokers
and current or past smokers, and the different BMI categories.
From probability distributions of menopausal ages based on
predictions from AMH falling below these thresholds, percentiles
for non-smokers and current or past smokers, and the different
BMI categories, were estimated and are shown in Table 3. And in
Table 4 are the corresponding percentiles of menopausal age
from similar modelling based on the critical AMH threshold
having no dependence on BMI and smoking status (cf. [19]), where
it can be seen that these percentiles are quite similar to those in
Table 3 for normal weight non-smokers which was the modal
category (with almost one-third of the data). These will give some
indication of likely age at menopause from the corresponding
percentile band where a woman’s age and AMH level was located
in Figure 2; for example, a woman with AMH between the 25-
and 50-percentiles who was of normal weight and a non-smoker or
over-weight and a current or former smoker could be expected to
experience menopause between 47 and 49.5 years of age
(Table 3). But if she were an overweight non-smoker then she
could expect almost another year before menopause, and about
one year less if a normal weight current or former smoker.
Discussion
Age at menopause varies widely in the female population;
indeed, the range for age at menopause is commonly believed to
be between 40 and 60 years [27]. The wide variability in age at
menopause is assumed to be the reflection of the high variability in
Figure 1. AMH data (dots) plotted on a logarithmic scale with smoothed mean (dashed line) similar to ref.19, and an estimate of the
mean as a quadratic function of age (solid line) with upper and lower 95% confidence limits (dotted lines).
doi:10.1371/journal.pone.0057005.g001
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ovarian reserve for women of similar ages. According to recent
models describing the rate of follicular decline with aging [13,14],
the pool of primordial follicles does vary widely in women of
similar ages. For example, at the age of 35 y the estimated range of
resting follicles in the ovary is between 19000 and 135000 [14].
Such high variability is then reflected in a higher variability of the
age at which primordial follicles will be exhausted and women
enter menopause.
Hence any biomarker indicating the number of resting follicles
may contribute to improvement in the prediction of menopause
based on age alone. AMH, a glycoprotein produced and secreted
by primary and preantral follicles, has been proposed as a reliable
measure of ovarian reserve. Indeed, serum AMH levels decrease
throughout reproductive life and are undetectable several years
before physiological menopause or following ovarian surgery [16].
With respect to other known markers, AMH seems to better reflect
the continuous decline of the follicular pool with age [20]. Some
years ago the possibility that AMH may permit prediction of age at
menopause was demonstrated in a cross sectional study based on
144 women [19]. In that study the predicted age at menopause
ranged from less than 41 years to more than 56 years according to
the age specific percentiles of AMH, whereby the lower age
specific AMH value, the lower the predicted age at menopause.
Subsequently the hypothesis has been confirmed by a 6-year
longitudinal study performed on 147 over 40-year old women
[28], which reported that a basal AMH lower than 0.39 ng/mL
may predict occurrence of menopause in the next 6 years with a
positive predictive value of 0.9 and a negative predictive value of
0.76. Both these groups of researchers recently published well-
designed longitudinal studies validating this hypothesis [21,29]. In
particular, in the Dutch study 257 women (aged 21–46 y) were
followed for 11 years; 19% of women experienced menopause in
this time frame and basal AMH was significantly related to time to
menopause and showed a good proportion of correct predictions
[29].
In the present study we have confirmed the good level of
conformity between the distribution of observed age at menopause
and predictions based on falling AMH levels. This enables
clinicians to have a useful assessment of the remaining reproduc-
tive life span, particularly for women in the age range 30–40 years
where the AMH-percentiles are quite well estimated.
The main contribution of this study has been that other
variables were used in addition to AMH in order to improve
prediction of age at menopause, namely BMI and smoking status.
A large (n=31000) Italian retrospective study [8] showed that low
BMI and smoking were both independently associated with early
age at menopause. Other retrospective and prospective studies
confirmed the positive correlation existing between BMI and age
at menopause [10,11,30]. Similarly, smoking has been repeatedly
reported as being associated with an earlier age at menopause
[8,9,10,11]. Our study confirms the influence of BMI and smoking
status on AMH-based prediction of age at menopause, by showing
that the threshold below which AMH predicts menopause varies
significantly with these covariates. However, estimates of the
actual thresholds were rather imprecise with up to a 7-fold
difference between the upper and lower 95% confidence limits,
and the latter below the detection limit of the AMH assay for some
covariate values (Table 2). This is due largely to similar
imprecision in the estimated mean AMH level at the mean age
of menopause (49.4 y) – see Figure 1.
Despite this imprecision, the modelled distributions of age at
menopause were quite precisely estimated (due to inter-depen-
dence between the AMH regression and AMH threshold
components of the modelling, whereby differences between these
can be better estimated than the individual components). The
variation in AMH necessary to describe the variation in
menopausal ages from predictions based on AMH falling below
Figure 2. Age-dependent AMH-percentiles: 5% & 95% (dotted lines), 10% & 90% (dash-dot-dash lines), 25% & 75% (dashed lines),
and 50% or median (solid line), with N denoting AMH level 2.5 ng/mL at age 30 years.
doi:10.1371/journal.pone.0057005.g002
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Figure 3. (a)–(f): comparisons of cumulative frequency distributions of age at menopause from the GOERM study (solid lines) and
model-based predictions from AMH falling below a critical threshold (dashed lines) for different BMI categories and smoking
status, showing quite good concordance between these. a): normal weight non-smokers ; (b): normal weight current or past smokers ; (c):
over-weight non-smokers ; (d): over-weight current or past smokers ; (e): obese non-smokers; (f): obese current or past smokers.
doi:10.1371/journal.pone.0057005.g003
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critical thresholds was significantly less than the residual variation
from the regression model of AMH and age, and consistent with
excess inter-and intra-cycle variation affecting these AMH data
whereby 76% of the age-adjusted AMH variance can be attributed
to variation between women (with 11% and 13% of the variance
due to inter- and intra-cycle variation, respectively, from
individual women [25]).
According to predictions without reference to BMI and smoking
(Table 4 and ref.19) a woman with AMH at the 10% age-specific
percentile level would be predicted to experience menopause at
about 44 years of age, while predictions range from 40.3 to 45.3
years if allowance is made for BMI and smoking status (Table 3).
Menopausal age will generally be lower for low BMI and for
current or past smokers (Table 3).
The combination of BMI and smoking status with AMH for
prediction of age at menopause is quite practicable since these two
covariates were not significantly associated with AMH levels.
While AMH seems to be lower in women with high BMI, any
association did not reach statistical significance when allowance
was made for age (i.e., older women tend to have lower AMH and
higher BMI than younger women). Several studies have reported a
negative association between smoking and AMH levels [31] while
others have reported non significant relationships [16,32]. The
largest cross-sectional study reporting on AMH, smoking and BMI
and based on 416 women from the general population [33] found
no age-independent correlation between AMH and both these
covariates.
Table 2. Estimated thresholds below which AMH predicts
menopause (with 95% confidence intervals in brackets)
according to smoking status and BMI categories.
BMI non-smoker current or past smoker
Under-weight 0.45 ng/mL (0.21, 0.97) 0.53 ng/mL (0.27, 1.07)
Normal weight 0.31 ng/mL (0.13, 0.74) 0.36 ng/mL (0.16, 0.81)
Over weight 0.25 ng/mL (0.09, 0.69) 0.30 ng/mL (0.12, 0.75)
Obese 0.28 ng/mL (0.11, 0.71) 0.33 ng/mL (0.14, 0.78)
doi:10.1371/journal.pone.0057005.t002
Table 3. Estimated percentiles of the probability distributions of age at menopause (6 standard errors in brackets) predicted by
AMH falling below critical thresholds according to smoking status and BMI categories.
AMH critical thresholds Body weight Predicted age at menopause (± standard error)
Non-smoker Current or past smoker
5u Under-weight 39 (1.6) 37.6 (1.8)
Normal weight 42.1 (0.2) 40.9 (0.3)
Over-weight 43.4 (0.3) 42.2 (0.3)
Obese 42.7 (0.3) 41.5 (0.4)
10u Under-weight 41.6 (1.3) 40.3 (1.5)
Normal weight 44.2 (0.2) 43.1 (0.2)
Over-weight 45.3 (0.2) 44.3 (0.3)
Obese 44.7 (0.2) 43.6 (0.8)
25u Under-weight 44.7 (1.1) 43.6 (1.2)
Normal weight 47 (0.1) 46 (0.2)
Over-weight 47.9 (0.1) 47 (0.2)
Obese 47.4 (0.2) 46.5 (0.2)
50u Under-weight 47.5 (1) 46.5 (1)
Normal weight 49.5 (0.1) 48.6 (0.2)
Over-weight 50.4 (0.1) 49.5 (0.2)
Obese 49.9 (0.2) 49 (0.2)
75u Under-weight 49.9 (0.9) 49 (0.9)
Normal weight 51.7 (0.1) 50.9 (0.2)
Over-weight 52.5 (0.1) 51.7 (0.2)
Obese 52.1 (0.2) 51.3 (0.2)
90u Under-weight 51.9 (0.8) 51.1 (0.9)
Normal weight 53.6 (0.1) 52.9 (0.2)
Over-weight 54.4 (0.1) 53.6 (0.2)
Obese 54 (0.2) 53.2 (0.2)
95u Under-weight 53.1 (0.8) 52.4 (0.9)
Normal weight 54.8 (0.1) 54.1 (0.2)
Over-weight 55.5 (0.1) 54.8 (0.2)
Obese 55.1 (0.2) 54.4 (0.2)
doi:10.1371/journal.pone.0057005.t003
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In conclusion, the present study confirms that serum AMH levels
enable the prediction of a woman’s reproductive life span, and that
that such prediction may be refined by other easily acquirable
information on BMI and smoking status that are associated with
age at menopause.
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